Marknadsnyheter

Calquence plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. standard of care in patients with untreated mantle cell lymphoma in ECHO Phase III trial

Published

4 månader ago

17 juni, 2024

Tanalys

First and only BTK inhibitor to demonstrate favourable overall survival trend vs. standard-of-care chemoimmunotherapy in this setting.

Positive results from the ECHO Phase III trial showed AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) and showed a favourable trend in overall survival (OS) compared to standard-of-care chemoimmunotherapy (bendamustine plus rituximab) in previously untreated patients with mantle cell lymphoma (MCL).

These results will be presented today in a late-breaking oral presentation at the European Hematology Association (EHA) 2024 Hybrid Congress in Madrid, Spain (#LBA3439).

Results showed the Calquence combination regimen reduced the risk of disease progression or death by 27% compared to standard-of-care chemoimmunotherapy (hazard ratio [HR] 0.73; 95% confidence interval [CI] 0.57-0.94; p=0.016). Median PFS was 66.4 months for patients treated with the Calquence combination (n=299) versus 49.6 months with standard-of-care chemoimmunotherapy (n=299).

The secondary endpoint of OS showed a favourable trend for the Calquence combination compared to standard-of-care chemoimmunotherapy, further supporting the clinical benefit of this combination (HR 0.86; 95% CI 0.65-1.13; p=0.2743). The OS data were not mature at the time of this analysis and the trial will continue to assess OS as a key secondary endpoint.

The ECHO trial enrolled during the pandemic period, and a pre-specified analysis censoring for COVID-19-related deaths was conducted to assess the impact. PFS was further improved in both arms, with the Calquence combination reducing the risk of disease progression or death by 36% (HR 0.64; 95% CI; 0.48-0.84; p=0.0017). Median PFS was not reached among patients treated with the Calquence combination versus 61.6 months for standard-of-care chemoimmunotherapy (HR 0.64, 95% CI, 0.48-0.84; p=0.0017). A favourable trend was seen for OS in this analysis for the Calquence combination (HR 0.75; 95% CI 0.53-1.04; p=0.0797).

Michael Wang, MD, Puddin Clarke Endowed Professor, Director of Mantle Cell Lymphoma Program of Excellence, Co-Director of Clinical Trials at MD Anderson Cancer Center in Houston, US and principal investigator in the trial, said: ”For people living with mantle cell lymphoma, a typically aggressive form of non-Hodgkin’s lymphoma, the ECHO results offer promise of a new, effective treatment option for adults older than 65, who represent the majority of MCL patients. The improved progression-free survival seen in patients treated with the Calquence combination compared to chemoimmunotherapy demonstrate its potential to change the standard of care as the only BTK inhibitor in this first-line setting.”

Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said: “The ECHO trial data demonstrate important progress in improving outcomes for patients with mantle cell lymphoma. The 16.8 months of additional time patients can live without their disease progressing is highly clinically meaningful, together with a trend to improvement in overall survival. We therefore believe Calquence plus chemoimmunotherapy will be an important new option for patients living with this disease.”

Summary of Results: ECHO

	Calquence plus bendamustine and rituximab(n = 299)	Placebo plus bendamustine and rituximab(n = 299)
Median PFS(months)	66.4	49.6
PFS HR (95% CI)	0.73 (0.57-0.94)
PFS p-value	0.0160
OS HR (95% CI)	0.86 (0.65-1.13)
OS p-value	0.2743
Censoring for COVID-19 deaths
Median PFS	NR	61.6
PFS HR (95% CI)	0.64 (0.48-0.84)
PFS p-value	0.0017
OS HR (95% CI)	0.75 (0.53-1.04)
OS p-value	0.0797

NR=Not reached

The safety and tolerability of Calquence was consistent with its known safety profile, and no new safety signals were identified. Grade 3 or higher adverse events (AEs) due to any cause occurred in 88.9% (n=264) of patients treated with the Calquence combination and 88.2% (n=262) of patients treated with standard-of-care chemoimmunotherapy, including Grade 3 or higher atrial fibrillation in 3.7% (n=11) and 1.7% (n=5) of patients, Grade 3 or higher hypertension in 5.4% (n=16) and 8.4% (n=25), Grade 3 or higher major bleeding in 2.0% (n=6) and 3.4% (n=10), and Grade 3 or higher infections in 41.1% (n=122) and 34.0% (n=101), respectively. Serious AEs and Grade 5 events were balanced across arms (69% [n=205] versus 62% [n=184], and 12.1% [n=36] versus 10.1% [n=30], respectively). AEs leading to discontinuation were observed in 10.4% (n=31) and 6.4% (n=19) of patients for the Calquence combination and placebo arms respectively. AEs related to COVID-19 were seen in the trial, including Grade 5 events which occurred in 9.4% (n=28) of patients treated with the Calquence combination and 6.7% (n=20) of patients treated with standard-of-care chemoimmunotherapy.

Additional AstraZeneca data at EHA

In addition to these compelling data, AstraZeneca data at EHA 2024 shows how the Company is advancing a diverse and innovative pipeline spanning multiple modalities including next-generation T cell engagers, cell therapy and antibody drug conjugates, to enable the creation of novel combination regimens across a range of blood cancers.

Results from the ongoing Phase I, dose-escalation trial of AZD0486, a novel CD19xCD3 T cell engager, showed durable responses in patients with heavily pretreated relapsed/refractory follicular lymphoma with a median follow up of 11 months. Complete response rates of 84% were seen at doses of AZD0486 of 2.4 mg and above. Data also showed how cytokine release syndrome (CRS) events were effectively mitigated by the double step-up dosing schedule and no immune effector cell-associated neurotoxicity syndrome (ICANS) events were observed.

In an oral presentation, preliminary data was shared from an investigator-initiated trial of AstraZeneca’s first haematology cell therapy, GC012F (AZD0120), in patients with transplant-eligible high-risk, newly diagnosed multiple myeloma. Early results showed that GC012F had an overall response rate of 100%, a minimal residual disease-negative stringent complete response rate of 95%, and was well tolerated. Grade 1-2 CRS was experienced by 27% (6/22) of patients and no ICANS or neurotoxicity was observed. GC012F is a novel BCMAxCD19 dual-targeting autologous chimeric antigen receptor T therapy (CAR-T) created using the next-day FasTCAR manufacturing platform pioneered by Gracell Biotechnologies, a wholly owned subsidiary of AstraZeneca.

Notes

Mantle cell lymphoma

MCL is a rare and typically aggressive form of non-Hodgkin lymphoma (NHL), often diagnosed as a late-stage disease, resulting when B-lymphocytes mutate into malignant cells within a region of the lymph node known as the mantle zone.^1,2 While MCL patients initially respond to treatment, patients do tend to relapse.³ MCL comprises about 3-6% of non-Hodgkin lymphomas, with an annual incidence of 0.5 per 100,000 population in Western countries; in the US, it is estimated that approximately 4,000 new patients are diagnosed with MCL each year.^3,4 It is estimated that there are more than 27,500 people living with MCL worldwide.^5,6

ECHO

ECHO is a randomised, double-blind, placebo-controlled, multi-centre Phase III trial evaluating the efficacy and safety of Calquence plus bendamustine and rituximab compared to standard of care chemoimmunotherapy (bendamustine and rituximab) in adult patients at or over 65 years of age (n=635) with previously untreated MCL.⁷ Patients were randomised 1:1 to receive either Calquence or placebo administered orally twice per day, on 28 day treatment cycles, plus bendamustine on days 1 and 2 and rituximab on day 1 of each cycle. After six cycles of induction therapy, all patients continued Calquence or placebo in combination with bendamustine and rituximab, patients receive Calquence or placebo plus maintenance rituximab for two years and then either Calquence or placebo only until disease progression.⁷

The primary endpoint is PFS assessed by an Independent Review Committee and key secondary endpoints include OS, overall response rate (ORR), duration of response (DoR) and time to response (TTR).⁷ The trial includes 27 countries across North and South America, Europe, Asia and Oceania.⁷

The ECHO trial enrolled patients from May 2017 to March 2023, continuing through the COVID-19 pandemic. Patients with blood cancer remain at a disproportionately high risk of severe outcomes from COVID-19, including hospitalisation and death compared to the general population.⁸

Calquence

Calquence (acalabrutinib) is a next-generation, selective inhibitor of Bruton’s tyrosine kinase (BTK). Calquence binds covalently to BTK, thereby inhibiting its activity.⁹ In B-cells, BTK signalling results in activation of pathways necessary for B-cell proliferation, trafficking, chemotaxis and adhesion.

Calquence has been used to treat more than 80,000 patients worldwide and is approved for the treatment of CLL and small lymphocytic lymphoma (SLL) in the US and Japan, approved for CLL in the EU and many other countries worldwide and approved in China for relapsed or refractory CLL and SLL. Calquence is also approved in the US, China and several other countries for the treatment of adult patients with MCL who have received at least one prior therapy. Calquence is not currently approved for the treatment of MCL in Japan or the EU.

As part of an extensive clinical development programme, Calquence is currently being evaluated as a single treatment and in combination with standard-of-care chemoimmunotherapy for patients with multiple B-cell blood cancers, including CLL, MCL, diffuse large B-cell lymphoma and follicular lymphoma.

AstraZeneca in haematology

AstraZeneca is pushing the boundaries of science to redefine care in haematology. Our goal is to help transform the lives of patients living with malignant, rare and other related haematologic diseases through innovative medicines and approaches that are shaped by insights from patients, caregivers and physicians.

In addition to our marketed products, we are spearheading the development of novel therapies designed to target underlying drivers of disease across six scientific platforms. Our recent acquisitions of Alexion, with expertise in rare, non-malignant blood disorders, and Gracell Biotechnologies Inc., focused on cell therapies for haematologic malignancies, expand our haematology pipeline and enable us to reach more patients with high unmet needs through the end-to-end development and delivery of novel therapies.

AstraZeneca in oncology

AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients.

The Company’s focus is on some of the most challenging cancers. It is through persistent innovation that AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyse changes in the practice of medicine and transform the patient experience.

AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.

AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca.

Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

References

Lymphoma Research Foundation. Mantle Cell Lymphoma. Available at: https://lymphoma.org/aboutlymphoma/nhl/mcl/. Accessed May 2024.
National Organization for Rare Disorders. Mantle Cell Lymphoma. Available at: https://rarediseases.org/rare-diseases/mantle-cell-lymphoma/. Accessed May 2024.
Cheah C, Seymour J, Wang ML. Mantle cell lymphoma. J Clin Oncol. 2016;34(11):1256-1269. doi: 10.1200/JCO.2015.63.5904.
MD Anderson Cancer Center. What to know about mantle cell lymphoma. Available at: https://www.mdanderson.org/cancerwise/what-to-know-about-mantle-cell-lymphoma-symptoms-diagnosis-and-treatment.h00-159385101.html. Accessed May 2024.
GLOBOCAN. Non-Hodgkin Lymphoma. Available at: https://gco.iarc.who.int/media/globocan/factsheets/cancers/34-non-hodgkin-lymphoma-fact-sheet.pdf. Accessed May 2024.
Lynch DT, Koya S, Acharya U, et al. Mantle Cell Lymphoma. Available at: https://www.ncbi.nlm.nih.gov/books/NBK536985/. Accessed May 2024.
ClinicalTrials.gov. A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL. Available at: https://clinicaltrials.gov/study/NCT02972840. Accessed May 2024.
Dube S, et al. Continued Increased Risk of COVID-19 Hospitalisation and Death in Immunocompromised Individuals Despite Receipt of ≥4 Vaccine Doses: Updated 2023 Results from INFORM, a Retrospective Health Database Study in England. Poster P0409 at ECCMID 2024.
Wu J, Zhang M, Liu D. Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor. J Hematol Oncol. 2016;9(21).

Marknadsnyheter

aXichem announces the result of the exercise of warrants series TO1A

Published

32 minuter ago

23 oktober, 2024

Tanalys

aXichem AB (publ) (”aXichem” or the ”Company”) today announces the outcome of the exercise of warrants series TO1A, which were issued in connection with the Company’s rights issue of units in March 2024. A total of 17,862,853 TO1A were exercised, corresponding to approximately 95 percent of the issued warrants, for subscription of 17,862,853 new shares of class A in aXichem. The subscription price per share was SEK 0.95. During the exercise period, the Company received guarantee commitments from a number of a number of qualified investors in the form of a so-called “top-down guarantee” of SEK 2.0 million, corresponding to approximately 11 percent of warrants series TO1A, which was announced on October 16, 2024. Since the subscription rate of warrants series TO1A amounted to approximately 95 percent, the top-down guarantee is claimed for 946,437 shares, corresponding to approximately SEK 0.9 million and approximately 5 percent of the issued warrants series TO1A. In light of this, the Board intends, with the support of the authorization from the annual general meeting on 19 June 2024, to resolve on a directed share issue of 946,437 shares to the guarantors. A separate press release will be published when the Board has resolved on the directed share issue. aXichem will receive approximately SEK 17.0 million before issue costs from the exercise of warrants series TO1A and the Company will further receive approximately SEK 0.9 million before issue costs from the directed share issue to the guarantors that the Board intends to resolve on. aXichem will thus, through the exercise of warrants series TO1A and through the directed share issue to the guarantors, receive a total of approximately SEK 17.9 million before issue costs, corresponding to a subscription rate of 100 percent of TO1A.

In total, 17,862,853 warrants series TO1A were exercised, corresponding to a subscription rate of approximately 95 percent, for subscription of 17,862,853 new shares of class A. Exercised TO1A has been replaced with interim shares pending registration with the Swedish Companies Registration Office. The interim shares are preliminarily expected to be converted to shares of class A during week 45, 2024. aXichem will receive approximately SEK 17.0 million before issue costs through the exercise of warrants series TO1A and will further receive approximately SEK 0.9 million before issue costs from the directed share issue to the guarantors that the Board intends to resolve on. aXichem will thus, through the exercise of TO1A and the directed share issue to the guarantors, receive a total of approximately SEK 17.9 million before issue costs, corresponding to a subscription rate of 100 percent of warrants series TO1A.

The Board intends to resolve on a directed share issue to the guarantors

The Company has previously communicated that, in the event that the guarantee commitments will be utilized, a supplementary directed share issue to the guarantors will be carried out after the exercise period of warrants series TO1A has ended. The result of the exercise of warrants series TO1A means that the top-down guarantee will be claimed. The guarantee means that the guarantors undertake to subscribe for the number of shares that remain in order for the exercise rate of warrants series TO1A to reach 100 percent of the issued warrants.

In light of the above, the Board of aXichem intends, with the support of the authorization from the annual general meeting on 19 June 2024, to resolve on a directed share issue of 946,437 shares to the guarantors, corresponding to approximately SEK 0.9 million and approximately 5 percent of the issued warrants of series TO1A. The subscription price in the directed share issue will, in accordance with the guarantee commitments and what has previously been communicated, be SEK 0.95 per share, which corresponds to the subscription price per share when exercising warrants series TO1A.

A separate press release will be published when the Board has resolved on the directed share issue.

Number of shares, share capital and dilution

Through the exercise of warrants series TO1A, the number of shares in the Company will increase by 17,862,853 shares, from 40,305,615 shares to 58,168,468 shares, and the share capital will increase by 3,572,570.60 SEK, from SEK 8,061,123 to 11,633,693.60 SEK, corresponding to a dilution of approximately 31 percent.

For more information:

Torsten Helsing, CEO, aXichem AB

Phone: +46 706 863 355, Email: torsten.helsing@axichem.com

Certified adviser for aXichem is Västra Hamnen Corporate Finance AB.

The information was submitted, through the agency of the above contact person, for publication on October 23, 2024, at 09:00 CEST.

About aXichem

aXichem develops, patents and markets natural analogue industrial chemicals, i.e., synthetically produced substances that have similar and comparable properties to natural substances. The company’s first product is phenylcapsaicin, which the company commercializes under two brands, aXiphen® and aXivite®, as an ingredient in animal feed and dietary supplements, respectively. The business is divided into three market areas with different applications for phenylcapsaicin: as an ingredient in feed for poultry, such as chicken and turkey, as an ingredient in food supplements for gut health, weight control and sports and exercise, and as an ingredient in food supplements for the bio-enhancement of curcumin and melatonin. aXichem is listed on the Nasdaq First North Growth Market. More information is available at www.axichem.com.

Marknadsnyheter

aXichem offentliggör utfall av utnyttjande av teckningsoptioner serie TO1A

Published

32 minuter ago

23 oktober, 2024

Tanalys

aXichem AB (publ) (“aXichem” eller “Bolaget”) meddelar idag utfallet från utnyttjandet av teckningsoptionerna serie TO1A, vilka emitterades i samband med Bolagets företrädesemission av units i mars 2024. Totalt utnyttjades 17 862 853 TO1A, motsvarande en teckningsgrad om cirka 95 procent, för teckning av 17 862 853 nya A-aktier i aXichem. Teckningskursen per aktie var 0,95 SEK. Under utnyttjandeperioden erhöll Bolaget garantiåtaganden från ett antal kvalificerade investerare i form av en så kallad toppgaranti om 2,0 MSEK, motsvarande cirka 11 procent av emissionsvolymen i TO1A, vilket offentliggjordes den 16 oktober 2024. Eftersom teckningsgraden uppgick till cirka 95 procent, tas toppgarantin i anspråk om 946 437 aktier, motsvarande cirka 0,9 MSEK och cirka 5 procent av emissionsvolymen i TO1A. Mot bakgrund av detta avser styrelsen, med stöd av bemyndigandet från årsstämman den 19 juni 2024, besluta om en riktad nyemission av 946 437 aktier till garanterna. Styrelsens beslut om riktad nyemission kommer offentliggöras i ett separat pressmeddelande när styrelsen fattat sådant beslut. aXichem tillförs genom TO1A cirka 17,0 MSEK före emissionskostnader och kommer att tillföras ytterligare cirka 0,9 MSEK före emissionskostnader genom den riktade nyemissionen till garanterna som styrelsen avser besluta om. aXichem kommer därmed, genom TO1A och den riktade nyemissionen till garanterna, totalt att tillföras cirka 17,9 MSEK före emissionskostnader, motsvarande en teckningsgrad om 100 procent av TO1A.

Totalt utnyttjades 17 862 853 TO1A, motsvarande en teckningsgrad om cirka 95 procent, för teckning av 17 862 853 nya A-aktier. Utnyttjade TO1A har ersatts med interimsaktier i väntan på registrering hos Bolagsverket. Interimsaktierna förväntas preliminärt konverteras till A-aktier under vecka 45, 2024. aXichem tillförs genom utnyttjandet av TO1A cirka 17,0 MSEK före emissionskostnader och kommer att tillföras ytterligare cirka 0,9 MSEK före emissionskostnader genom den riktade nyemissionen till garanterna som styrelsen avser besluta om. aXichem kommer därmed, genom TO1A och den riktade nyemissionen till garanterna, totalt att tillföras cirka 17,9 MSEK före emissionskostnader, motsvarande en teckningsgrad om 100 procent av TO1A.

Styrelsen avser besluta om riktad nyemission till garanterna

Bolaget har tidigare kommunicerat att för det fall garantiåtagandena tas i anspråk kommer det att genomföras en kompletterande riktad nyemission av aktier till garanterna efter att nyttjandeperioden för TO1A avslutats. Utfallet för utnyttjande av TO1A innebär att toppgarantin tas i anspråk. Toppgarantin innebär att garanterna åtar sig att teckna det antal aktier som återstår för att utnyttjandegraden ska uppgå till 100 procent av emissionsvolymen av teckningsoptionerna serie TO1A.

Styrelsen för aXichem avser mot bakgrund av ovan, med stöd av bemyndigandet från årsstämman den 19 juni 2024, besluta om en riktad nyemission av 946 437 aktier till garanterna, motsvarande cirka 0,9 MSEK och cirka 5 procent av emissionsvolymen i TO1A. Teckningskursen i den riktade nyemission kommer, i enlighet med garantiavtalen och vad som tidigare kommunicerats, vara 0,95 SEK per aktie, vilket motsvarar teckningskursen per aktie vid utnyttjande av TO1A.

Styrelsens beslut om riktad nyemission kommer offentliggöras i ett separat pressmeddelande när styrelsen fattat sådant beslut.

Antal aktier, aktiekapital och utspädning

Genom utnyttjandet av TO1A ökar antalet aktier i Bolaget med 17 862 853 aktier, från 40 305 615 aktier till 58 168 468 aktier, och aktiekapitalet ökar med 3 572 570,60 SEK, från 8 061 123 SEK till 11 633 693,60 SEK, motsvarande en utspädningseffekt om cirka 31 procent.

För mer information:

Torsten Helsing, VD, aXichem AB

Tel: +46 706 86 33 55 E-post: torsten.helsing@axichem.com

Certified adviser åt aXichem är Västra Hamnen Corporate Finance AB.

Informationen lämnades, genom ovanstående kontaktpersons försorg, för offentliggörande den 23 oktober 2024 kl. 09:00 CEST.

Om aXichem

aXichem utvecklar, patenterar och marknadsför naturanaloga industrikemikalier, det vill säga syntetiskt framställda substanser som har likartade och jämförbara egenskaper som naturliga substanser. Bolagets första produkt är phenylcapsaicin, som Bolaget kommersialiserar under två varumärken, aXiphen® och aXivite®, som ingrediens i djurfoder respektive kosttillskott. Verksamheten är uppdelad i tre marknadsområden med olika applikationer för phenylcapsaicin: som ingrediens i foder för fjäderfän, så som kyckling och kalkon; som ingrediens i kosttillskott för tarmhälsa, viktkontroll samt sport och träning; samt som ingrediens i kosttillskott för biotillgänglighetsförstärkning av curcumin och melatonin. aXichem är listat på Nasdaq First North Growth Market.
Mer information finns på www.axichem.com

Marknadsnyheter

Gympak och Centrovital Berlin lanserar samarbete med innovativ fitnesslösning för hotellgäster

Published

34 minuter ago

23 oktober, 2024

Tanalys

Det fyrstjärniga superiorhotellet har officiellt blivit det första hotellet i Tyskland att erbjuda Gympaks innovativa lösningar. Detta samarbete introducerar möjligheten för gäster att låna träningskläder och fitnessutrustning direkt till sina rum, vilket ytterligare förbättrar hotellets redan imponerande spa- och gymfaciliteter.

Hotellet har 158 välutrustade rum och erbjuder omfattande hälso- och välbefinnandetjänster, inklusive en 25-meters simbassäng, ett toppmodernt gym och en generös spaanläggning. Det är nu det första hotellet i Tyskland som samarbetar med Gympak, vilket gör det möjligt för gäster att hyra träningskläder och utrustning direkt till sina rum, och därigenom förhöja sin träningsupplevelse under vistelsen. Detta samarbete syftar till att öka gästnöjdheten genom att göra fitnesstjänster mer tillgängliga och bekväma.

Viktor Weinbender, Front Office Manager på Centrovital Hotel Berlin, uttryckte sin entusiasm över samarbetet: ”Vi är glada att kunna erbjuda Gympaks banbrytande fitnesstjänst till våra gäster. Det ger en ny nivå av bekvämlighet, vilket gör att våra gäster kan vara aktiva oavsett var de befinner sig på hotellet, inklusive från bekvämligheten av sina egna rum.”

Tar hotellfitness till nya höjder
Detta samarbete markerar en spännande utveckling i Gympaks uppdrag att tillhandahålla tillgängliga och bekväma fitnesslösningar för hotell över hela Europa. Tjänsten är utformad för att öka gästnöjdheten genom att erbjuda ett smidigt sätt för gäster att upprätthålla sina träningsrutiner under resan. Med Centrovital Berlin i spetsen är Gympak redo att expandera sin närvaro och ge fler hotell i Tyskland verktygen för att revolutionera sina gästers upplevelse.

Stephan Wachsmuth, hotellets General Manager, delade sina tankar: ”Vårt mål är att erbjuda en förstklassig fitnessupplevelse för våra gäster. Genom att samarbeta med Gympak kan vi förbättra våra fitnesstjänster och stödja våra gäster i att upprätthålla sin hälsa och sitt välbefinnande under hela vistelsen. Detta initiativ är särskilt värdefullt för våra affärsresenärer, seminarie- och konferensdeltagare, samt våra wellness-gäster. De kan utnyttja de omfattande faciliteterna i vårt exceptionella Spa och Sports Club i Berlin-Spandau, som har en stor medlemsbas. Genom vårt omfattande kursprogram har gästerna också flexibiliteten att spontant delta i pass under sitt besök, vilket ytterligare berikar deras vistelse hos oss.”

Gympaks VD, Jone Sølvik, kommenterade expansionen: ”Vi är otroligt tacksamma för det förtroende Centrovital har visat oss. Detta partnerskap markerar vårt inträde på den tyska marknaden, och vi ser fram emot att göra en verklig skillnad här. Vi ser fram emot att se hur gästerna reagerar på denna nya nivå av bekvämlighet, och vi är övertygade om att det kommer leda till många ’wow’-ögonblick.”

Gäster kan nu njuta av en unik fitnessupplevelse i Berlin, oavsett om de väljer att träna på gymmet, i spat eller direkt på sina hotellrum med Gympaks tjänster. Detta innovativa erbjudande hjälper gäster att prioritera sin hälsa och sitt välbefinnande, vilket gör det möjligt för dem att hålla sig aktiva medan de njuter av alla bekvämligheter som hotellet har att erbjuda.

För mer information:
Jone Sølvik, VD Gympak, jone.solvik@gympak.com, +46 706 112 100
Stephan Wachsmuth, General Manager, swachsmuth@centrovital-berlin.de
Viktor Weinbender, Front Office Manager, vweinbender@centrovital-berlin.de

Om Gympak:
Gympak är ett svenskt företag som erbjuder innovativa wellness-lösningar för hotell. Företaget gör det enkelt för hotellgäster att ta hand om sin hälsa genom att erbjuda träningsutrustning, kläder och personliga träningsprogram som kan nyttjas direkt på hotellrummet.

Om Centrovital:
År 2004, efter flera års renovering, öppnades den kulturmärkta byggnaden på Brauereihof nr. 6 under namnet ”Centrovital”. Beläget i Berlins City West, nära Havel, kombinerar Centrovital nu ett hotell, ett Spa & Sports Club, ett Day Spa & Ayurveda Centre, och ett brett utbud av gastronomiska alternativ under ett tak. Gäster kan förvänta sig 158 moderna rum och sviter, tolv multifunktionella eventrum för affärs- och privata evenemang, Emil’s Restaurant med en rymlig terrass, La Havanita Bar & Bistro, och en Rooftop Bar.

Centrovital Spa och Sports Club för gäster och medlemmar erbjuder multimedia Technogym®-utrustning, Functional Tower, SKILLMILL™, Kinesis® track, Galileo® vibrationsträning, personlig träning och ett varierat kursprogram. ”SCANECA”, ett revolutionerande holistiskt 3D-kroppsanalys system ”Made in Germany”, är också tillgängligt. Med hjälp av en detaljerad 3D-avatar mäts relevanta kroppsomfång snabbt och exakt, hållning analyseras och en detaljerad rapport över de viktigaste hälsorelaterade kroppsvärdena skapas. SCANECA-teknologin utvecklades under tre års forsknings- och utvecklingsarbete i Berlin av ett team av vetenskapsmän och experter i samarbete med Humboldt-Innovation vid Humboldtuniversitetet i Berlin. SCANECA-teamet hedrades av ”Stifterverband” för denna unika innovation.

I spa- och bastuområdet inbjuder en 25-meters pool, bubbelpool, fem bastur och takterrassen till avkoppling. Isigloon kyler dig efter bastubadet. I det närliggande Ayurveda Centre kan du njuta av ett omfattande urval av traditionella ayurvediska behandlingar; Day Spa erbjuder klassiska wellness- och skönhetsbehandlingar.

Taggar: